Related Experiment Videos
Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes
1Emory University School of Medicine, Atlanta, GA, USA.
Insights
Intravenous haloperidol can prolong the QT interval in patients with acute coronary syndromes, potentially leading to dangerous ventricular arrhythmias like ventricular fibrillation. Close monitoring of QT intervals is crucial when using haloperidol in these high-risk patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Acute coronary syndromes (ACS) represent a critical condition requiring prompt management.
- Haloperidol, a typical antipsychotic, is sometimes used for managing agitation or delirium in medically ill patients.
- QT interval prolongation is a known risk factor for potentially fatal cardiac arrhythmias.
Observation:
- Three patients with ACS experienced QT interval prolongation after receiving intravenous haloperidol.
- One of these patients developed ventricular fibrillation, a life-threatening arrhythmia.
- A literature review identified an additional 21 cases of similar adverse events.
Findings:
- Intravenous haloperidol is associated with QT interval prolongation in patients with ACS.
- This prolongation increases the risk of ventricular ectopy and potentially fatal arrhythmias.
- The risk appears elevated in patients with underlying coronary ischemia.
Implications:
- Clinicians should exercise caution when prescribing intravenous haloperidol to patients with ACS.
- Close electrocardiographic monitoring, specifically of the QT interval, is recommended.
- Alternative antipsychotic agents with a lower risk profile for QT prolongation may be considered in this patient population.
Abstract:
We report on three patients with acute coronary syndromes who developed QT interval prolongation associated with intravenous haloperidol use. One developed ventricular fibrillation. We also review 21 such patients from the literature. Haloperidol should be used with caution and QT intervals monitored closely in patients with coronary ischemia who may be prone to ventricular ectopy.